FDA investigating cancer risk after CAR-T therapy

The U.S. Food and Drug Administration is investigating whether certain cancer treatments can increase risk for secondary cancers, according to CNN Health. The agency has received 19 reports of T-cell malignancies among people who were previously treated with certain chimeric antigen receptor T-cell (CAR-T) therapies. The FDA approved the first CAR-T cancer therapy in 2017, and required 15-year follow-up studies to asses long-term safety.